medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 2

<< Back Next >>

Med Int Mex 2018; 34 (2)

Kikuchi-Fujimoto disease in presentation with silicosis

Bolaños-Aguilar MA, Celis-Vera KD, Barragán-Garfias JA, Orrantia-Vértiz M, Duarte-Mote J

Language: Spanish
References: 23
Page: 335-341
PDF size: 385.65 Kb.


ABSTRACT

Kikuchi-Fujimoto disease, also called histiocytic necrotizing lymphadenitis, is a rare and benign condition of unknown etiology, characte rized by cervical lymphadenopathy with fever that frequently occurs in previously young healthy women. The clinical manifestations, a history of systemic lupus erythematous and histopathologic analysis suggest an immune response of T cells and histiocytes as a part of the pathophysiology. The diagnosis of Kikuchi disease requires lymph node biopsy, in which there is evidence of necrosis with histiocyte infiltrates and characteristically absence of neutrophils. No effective treatment exists for Kikuchi disease, it is self-limited into 1-4 weeks; with severe and persistent symptoms, glucocorticoids and nonsteroidal anti-inflammatory drugs are prescribed. Silicosis is a condition in which silicone, a component of breast implants, acts as an immunogenic adjuvant, causing a local and systemic autoimmune response with non-specific symptomatology constituting the adjuvant-induced autoimmune syndrome (ASIA). The treatment of ASIA is based on the elimination of the external stimulus and in most cases a favorable long-term response is observed without initiating immunomodulatory treatment. More cases are needed in order to establish silicosis as a cause of Kikuchi-Fujimoto disease and to know more about the relationship between these conditions.


REFERENCES

  1. Bosch X, Guilabert A. Kikuchi-Fujimoto disease. Orphanet J Rare Dis 2006;1:18.

  2. Baenas DF, Diehl FA, Haye María J, Riva V, Diller A, Lemos P. Kikuchi-Fujimoto disease and systemic lupus erytematosus. Int Med Case Rep J 2016;9:163-167.

  3. Sharma V, Rankin R. Fatal Kikuchi-like lymphadenitis associated with connective tissue disease: a report of two cases and review of the literature. SpringerPlus 2015;4:167.

  4. Kucukardali Y, Solmazgul E, Kunter E, Oncul O, Yildirim S, Kaplan. Kikuchi-Fujimoto Disease: analysis of 244 cases. Clin Rheumatol 2007;26:50-54.

  5. Mathew L, Kapila R, Schwartz R. Kikuchi-Fujimoto disease: a diagnostic dilema. Int J Dermatol 2016;1-7.

  6. Deaver D, Horna P, Cualing H, Sokol L. Pathogenesis, diagnosis and management of Kikuchi-Fujimoto disease. Cancer Control 2014;21:313-321.

  7. Gutiérrez M, De León B, Cuesta T, Baquera J, Padilla A, Ortiz C. Enfermedad de Kikuchi-Fujimoto (linfadenitis histiocítica necrosante). Estudio clinicopatológico e inmunohistoquímico de 14 casos y su diagnóstico diferencial con otras linfadenitis necrosantes reactivas y neoplásicas. Rev Invest Clin 2006;52:441-449.

  8. Torres JJ, Martín E, Íñiguez A. Síndrome autoinmune/ autoinflamatorio inducido por adyuvantes. Rev Med MD 2016;7(3):170-181.

  9. Hajdu Steven, Agmon N, Shoenfeld Y. Silicone and autoimmunity. Eur J Clin Invest 2011;41(2):203-2011.

  10. Goren I, Segal G, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) evolution after silicone implants. Who is at risk? Clin Rheumatol 2015;34:1661-1666.

  11. Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. Lupus 2015;24:7.

  12. Shapiro E. Lyme disease. N Engl J Med 2014;370:1724-31.

  13. Wormser G. Early Lyme disease. N Engl J Med 2006;354:2794-801.

  14. Feder H, Johnson B, O’Connell S, et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med 2007;357:1422-30.

  15. Berende A, Hofstede H, Vos F, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med 2016;374:1209-20.

  16. Nadelman R, Haninková K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012;367:1883-90.

  17. Plotkin S. Need for a new Lyme disease vaccine. N Engl J Med 2016 DOI: 10.1056/NEJMp1607146.

  18. Hofhuis A, Kassteele J, Sprong H. Predicting the risk of Lyme borreliosis after a tick bite, using a structural equation model. Plos One 2017;12(7):e0181807.

  19. Puri B, Hakkarainen S, Monro J. The effect of artesunate on short-term memory in Lyme borreliosis. Med Hypotheses 2017;105:4-5.

  20. García M, Skinner C, Salas J. Enfermedad de Lyme: actualizaciones. Gac Méd Méx 2014;150:84-95.

  21. Gordillo M, Solórzano F. Enfermedad de Lyme. Experiencia en niños mexicanos. Bol Med Hosp Infant Mex 2010.

  22. Skinner C, Flores M, Esquivel J, et al. Evidencia de la enfermedad de Lyme en una población de alto riesgo del noreste de México. Medicina Universitaria 2007;9(36):105-11.

  23. Gordillo G, Torres J, Solórzano F, et al. Estudio seroepidemiológico de borreliosis de Lyme en la Ciudad de México y el noreste de la República Mexicana. Salud Púb Méx 2003:45(5).




2020     |     www.medigraphic.com